Biocardia stock.

Mohammed Haneefa Nizamudeen. I first wrote about BioCardia (NASDAQ:BCDA) in June of 2021, explaining why I'd taken a speculative-sized position in the stock.Since then the share price is down (as ...BioCardia Inc. analyst ratings, historical stock prices, earnings estimates & actuals. BCDA updated stock price target summary.The upgrade of BioCardia, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term ...BioCardia (BCDA) In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on BioCardia, with a price target of $4.00 . The company’s shares closed last Tuesday ...2023 BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval 16 Nov 2023 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

Sep 5, 2023 · The latest update sent BioCardia’s stock down around 20% to 62 cents in premarket trading, adding to losses that have seen the share price slide by more than 60% in six months.

Stock Price Forecast. The 1 analysts offering 12-month price forecasts for BioCardia Inc have a median target of 4.00, with a high estimate of 4.00 and a low estimate of 4.00. The median estimate ...BioCardia Inc BCDA shares are down after the company released interim efficacy results in the phase 3 pivotal CardiAMP cell therapy heart failure trial.. For the first tier, all-cause death ...

BioCardia, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 Nov. 08: CI BioCardia Files $50 Million Mixed Shelf; Shares Rise Oct. 20: MT BioCardia, Inc. Elects Bill Facteau as Class I Director Oct. 18BioCardia Inc. Stock Earnings. The value each BCDA share was expected to gain vs. the value that each BCDA share actually gained. BioCardia Inc. ( BCDA) reported Q2 2023 earnings per share (EPS) of -$0.17, missing estimates of -$0.16 by 7.23%. In the same quarter last year, BioCardia Inc. 's earnings per share (EPS) was -$0.14.Nov 18, 2023 · BioCardia Stock Down 10.0 %. NASDAQ BCDA opened at $0.72 on Tuesday. The stock has a market capitalization of $15.59 million, a P/E ratio of -1.16 and a beta of 1.29. BioCardia has a 52-week low of $0.36 and a 52-week high of $2.92. The firm has a 50-day moving average price of $0.44 and a 200 day moving average price of $1.26. Discover historical prices for BCDA stock on Yahoo Finance. View daily, weekly or monthly format back to when BioCardia, Inc. stock was issued.Stock Price Forecast. According to 1 stock analyst, the 12-month stock price forecast for BioCardia stock is $4.00, which predicts an increase of 543.92%. On average, analysts rate BioCardia stock as a strong buy.

SUNNYVALE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...

2023 BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval 16 Nov 2023 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

BioCardia Inc ( BCDA) is lower by Wednesday morning, with the stock declining -4.67% in pre-market trading to 1.02. BCDA's short-term technical score of 100 indicates that the stock has traded more bullishly over the last month than 100% of stocks on the market. In the Biotechnology industry, which ranks 123 out of 146 industries, the …BioCardia Inc stock performance at a glance. Check BioCardia Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.Simon Stertzer owns over 166,666 units of BioCardia stock worth over $1,611,493 and over the last 7 years he sold BCDA stock worth over $0. In addition, he makes $76,250 as Independent Chairman of the Board at BioCardia. Wallmine is a radically better financial terminal. Sign up in seconds, it's free!BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq ...BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 14d Why Beyond Air Shares Are Trading Lower By Around 37%?

You can buy and sell BioCardia (BCDA) and other stocks, ETFs, and options commission-free on Robinhood with real-time quotes, market data, and relevant news. Other Robinhood Financial fees may apply, check rbnhd.co/fees for details. ... BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of developing cellular ...Nov 15, 2023 · BioCardia Inc’s (NASDAQ: BCDA) stock has experienced a remarkable surge of 225.70% following the FDA’s recent approval of the Phase 3 CardiAMP Heart Failure II study protocol for their innovative CardiAMP autologous cell therapy for ischemic heart failure. 5 Sep 2023 ... Biocardia stock dropped from about $2 on July 21 to $1.10 on July 24, when the concerns of the DSMB were first revealed. After drifting down ...Allan Tessler BCDA stock SEC Form 4 insiders trading. Allan has made over 11 trades of the BioCardia stock since 2006, according to the Form 4 filled with the SEC. Most recently Allan bought 400 units of BCDA stock worth $199,200 on 9 March 2020.. The largest trade Allan's ever made was buying 20,000 units of BioCardia stock on 21 …Nov 8, 2023 · BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 0% and 614%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? Simon Stertzer BCDA stock SEC Form 4 insiders trading. Simon has made over 15 trades of the BioCardia stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 166,666 units of BCDA stock worth $999,996 on 5 July 2019.. The largest trade he's ever made was buying 3,333,332 units of BioCardia stock on 24 …

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive ...

Analysts who follow BioCardia Inc on average expect it to increase 1150.00% over the next twelve months. Those same analysts give the stock an average rating of Buy. That average rating earns BioCardia Inc an Analyst Ranking of 25, which means it ranks higher than 25 of stocks, based on data compiled by InvestorsObserver.BioCardia Inc BCDA shares are down after the company released interim efficacy results in the phase 3 pivotal CardiAMP cell therapy heart failure trial.. For the first tier, all-cause death ...Richard has made over 43 trades of the BioCardia stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of BCDA stock worth $14,600 on 17 June 2019.Nov 29, 2023 · See the latest BioCardia Inc stock price (BCDA:XNAS), related news, valuation, dividends and more to help you make your investing decisions. 6 hari yang lalu ... BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected ...Analysts who follow BioCardia Inc on average expect it to increase 1150.00% over the next twelve months. Those same analysts give the stock an average rating of Buy. That average rating earns BioCardia Inc an Analyst Ranking of 25, which means it ranks higher than 25 of stocks, based on data compiled by InvestorsObserver.SUNNYVALE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...Discover historical prices for ME stock on Yahoo Finance. View daily, weekly or monthly format back to when 23andMe Holding Co. stock was issued.BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today …

BioCardia, Inc. (BCDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BioCardia (NASDAQ:BCDA) Third Quarter 2023 Results Key Financial Results. Revenue: US$357.0k (up 68% from 3Q 2022). ... It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by …

Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 29, 2023, under the caption titled ...Nov 26, 2023 · Website. n/a. 33. Peter Altman. https://www.biocardia.com. BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of ... 16 Nov 2023 ... BioCardia develops cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. Stock BCDA logo. BioCardia ...BioCardia (NASDAQ:BCDA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better investment?We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability, media sentiment, risk and valuation.Mohammed Haneefa Nizamudeen. I first wrote about BioCardia (NASDAQ:BCDA) in June of 2021, explaining why I'd taken a speculative-sized position in the stock.Since then the share price is down (as ...BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.2023. 2023 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. 14 Nov. 2023 BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure. 2023 BioCardia Reports Third Quarter 2023 Business Highlights and …The estimated Net Worth of David Mc Clung is at least $440 Thousand dollars as of 5 November 2018. Mr. Clung owns over 1,600 units of BioCardia stock worth over $5,952 and over the last 6 years he sold BCDA stock worth over $0. In addition, he makes $434,495 as Chief Financial Officer at BioCardia.Convert Biocardia Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Select a stock. apple; wise; Select a currency. USD. NASDAQ: Biocardia Inc (BCDA) = 0.68 USD. Provided by Alpha Vantage. Biocardia Inc stock (BCDA) in USD. 1 BCDA = 0.68 USD. 1 month.Mohammed Haneefa Nizamudeen. I first wrote about BioCardia (NASDAQ:BCDA) in June of 2021, explaining why I'd taken a speculative-sized position in the stock.Since then the share price is down (as ...Stock screener. Filter, compare, and track stocks. Commerce des membres de la sociét ... As the Vice President - Operations of BioCardia, the total compensation of Phil Pesta at BioCardia is $276,000. There are 5 …

Stock analysis for BioCardia Inc (BCDA:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.BioCardia ( NASDAQ: BCDA) shares jumped over +105% premarket on Tuesday after the biotech firm received FDA approval for the Phase 3 clinical trial of its CardiAMP autologous cell therapy for the ...BioCardia Inc (BCDA) stock is trading at $2.16 as of 10:19 AM on Friday, Jun 9, an increase of $0.04, or 1.89% from the previous closing price of $2.12. The stock has traded between $2.15 and $2.18 so far today. Volume today is light. So far 5,707 shares have traded compared to average volume of 41,498 shares.The estimated Net Worth of Richard M Krasno is at least $297 Thousand dollars as of 17 June 2019. Mr. Krasno owns over 20,000 units of BioCardia stock worth over $27,300 and over the last 17 years he sold BCDA stock worth over $0. In addition, he makes $269,814 as Independent Director at BioCardia.Instagram:https://instagram. innovation refunds google reviewsbest rated jewelry insurance companiesbest investments for 100krevology cars BioCardia, Inc. Common Stock (BCDA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Nov 20, 2023 · The stock of BioCardia Inc. (BCDA) has seen a 84.85% increase in the past week, with a 84.37% gain in the past month, and a -16.66% decrease in the past quarter. The volatility ratio for the week is 30.21%, and the volatility levels for the past 30 days are at 12.77% for BCDA. The simple […] best currency trading sitesinvestment real estate agency Biocardia trades on the NASDAQ stock market under the symbol BCDA. What is Biocardia stock price doing today? As of November 29, 2023, BCDA stock price declined to $0.68 with 702,007 million shares trading.6 hari yang lalu ... BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of ... posc Nov 8, 2023 · BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 0% and 614%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? BioCardia ®, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation for the CardiAMP ® Cell Therapy System for the treatment of heart failure. It is believed to be the first cardiac …A new COVID variant, HV.1, is now dominant. These are its most common symptoms. Deer hunting is dying. That should worry you even if you don't hunt. The FDA approved BioCardia Inc's (NASDAQ: BCDA ...